It’s only fair to share… PRN-473 SAR-444727 1414354-91-8 C30 H30 F N7 O2 Molecular Weight539.60 1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-α-(2,2-dimethylpropylidene)-β-oxo-, (3R)- (3R)-3-[4-Amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-α-(2,2-dimethylpropylidene)-β-oxo-1-piperidinepropanenitrile 2-(3-(4-amino~3-(2-fiuoro~4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile OriginatorPrincipia Biopharma ClassSmall molecules Mechanism of ActionAgammaglobulinaemia tyrosine kinase inhibitors Phase IAutoimmune disorders DiscontinuedArthritis 28 Sep 2020Principia Biopharma has been acquired by Sanofi 22 Jun 2020Principia Biopharma plans a pharmacokinetic phase I trial (In volunteers) for Hypersensitivity …
Tag «PHASE 1»
PF-07321332, Nirmatrelvir
It’s only fair to share… PF-07321332, nirmatrelvir UNII-7R9A5P7H32, 7R9A5P7H32, PF07321332 CAS 2628280-40-8, C23H32F3N5O4, 499.5 (1R,2S,5S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide Paxlovid (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-6,6-dimethyl-3-(3-methyl-N-(trifluoroacetyl)-L-valyl)-3-azabicyclo(3.1.0)hexane-2-carboxamide https://clinicaltrials.gov/ct2/show/NCT04756531 join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join me on Researchgate RESEARCHGATE join me on Facebook Anthony Melvin Crasto Dr. | Facebook Twitter FACEBOOK join me on twitter Anthony Melvin Crasto Dr. | twitter +919321316780 call whatsaapp EMAIL. amcrasto@amcrasto ///////////////////////////////////////////////////////////////////////////// SYN https://pubmed.ncbi.nlm.nih.gov/34726479/ …
ABBV 744
It’s only fair to share… ABBV 744 N-Ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl]-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl]-6,7-dihydro-6-methyl-7-oxo- Molecular Weight 491.55 Formula C₂₈H₃₀FN₃O₄ CAS No. 2138861-99-9 ABBV-744 is a highly BDII-selective BET bromodomain inhibitor, used in the research of inflammatory diseases, cancer, and AIDS. Acute Myeloid Leukemia (AML) Phase I, AbbVie is evaluating oral agent ABBV-744 in early clinical trials for the treatment of metastatic castration …
CC-90010
It’s only fair to share… CC-90010 C21 H21 N O4 S, 383.46 CAS 1706738-98-8 1(2H)-Isoquinolinone, 4-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl- 4-[2-(Cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl-1(2H)-isoquinolinone 4-[2-(Cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one 4-[2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Quanticel Pharmaceuticals Inc, Michael John BennettJuan Manuel BetancortAmogh BoloorStephen W. KaldorJeffrey Alan StaffordJames Marvin Veal Celgene (now a wholly owned subsidiary of Bristol-Myers Squibb ) , following its acquisition of Quanticel , is developing CC-90010, an oral inhibitor of BET (bromodomain and extraterminal) …
IIIM-290
It’s only fair to share… IIIM-290 4H-1-Benzopyran-4-one, 2-[2-(2,6-dichlorophenyl)ethenyl]-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]- Molecular Weight 462.32 Formula C₂₃H₂₁Cl₂NO₅ CAS No. 2213468-64-3 CSIR-IIIM Jammu has filed an IND Application of “IIIM-290” to Drug Controller General of India for conducting Phase I/Phase II clinical trial of its capsule formulation in patients with locally advanced or metastatic pancreatic cancer. This IND candidate …
J-147
It’s only fair to share… J-147 N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide Molecular FormulaC18H17F3N2O2 Average mass350.335 Da 2,2,2-trifluoroacetic acid-1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(1E)-(3-methoxyphenyl)methylene]hydrazide N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide [1146963-51-0] 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide, 2,2,2-trifluoro-acetic acid 1146963-51-0 [RN] DOUBLE BOND GEOMETRY UNSPECIFIED 1807913-16-1 [RN] AS PER https://chem.nlm.nih.gov/chemidplus/sid/1807913161 E FORM FDA UNII Z41H3C5BT9 Abrexa Pharmaceuticals, Dementia, Alzheimer’s type, PHASE1 Blanchette Rockefeller Neurosci Inst (Originator) Salk Institute for Biological Studies (Originator) Abrexa Pharmaceuticals is …
AK-3280
It’s only fair to share… AK-3280 AK 3280; GDC3280; RG 6069 C19 H15 F3 N4 O2, 388.34 CAS 1799412-33-1 4H-Benzimidazol-4-one, 1,5-dihydro-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-[4-(trifluoromethoxy)phenyl]- Ci8Hi4N502F3, mass 389.3 g/mol), ROCHE, Ark Biosciences , under license from Roche , is developing AK-3280, an antifibrotic agent, for the potential oral treatment of IPF. In July 2018, Ark intended to further clinical development of the drug, for IPF. …
SY-008
It’s only fair to share… SY-008 CAS 1878218-66-6 FREE FORM 1480443-32-0 SGLT1 inhibitor (type 2 diabetes), β-D-Glucopyranoside, 4-[[4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)-1-buten-1-yl]-2-methylphenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl, acetate (1:1) acetic acid;(2S,3R,4S,5S,6R)-2-[[4-[[4-[(E)-4-(2,9-diazaspiro[5.5]undecan-2-yl)but-1-enyl]-2-methylphenyl]methyl]-5-propan-2-yl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D-glucopyranoside acetate MF H50 N4 O6 . C2 H4 O2 MW 58.8 g/mol,C35H54N4O8 Originator Eli Lilly Developer Eli Lilly; Yabao Pharmaceutical Group Class Antihyperglycaemics; Small molecules Mechanism of Action Sodium-glucose transporter 1 inhibitors Phase I Diabetes mellitus 28 Aug 2018 No recent reports of …
Picropodophyllin
It’s only fair to share… Picropodophyllin Picropodophyllotoxin CAS 477-47-4 AXL1717, NSC 36407, BRN 0099161 414.4 g/mol, C22H22O8 (5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Furo(3′,4′:6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5-alpha,5a-alpha,8a-alpha,9-alpha))- 5-19-10-00665 (Beilstein Handbook Reference) Axelar is developing picropodophyllin, a small-molecule IGF-1 receptor antagonist for the treatment of cancer including NSCLC and malignant astrocytoma. In February 2019, a phase Ia study was planned to initiate for solid tumor …
HEC-68498
It’s only fair to share… HEC-68498, CT-365 CAS 1621718-37-3 C20 H13 F2 N5 O3 S 441.41 Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- N-[5-(3-Cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluorobenzenesulfonamide HEC Pharm , Calitor Sciences Llc; Sunshine Lake Pharma Co Ltd PHASE 1, idiopathic pulmonary fibrosis and solid tumors Phosphoinositide 3-kinase inhibitor; mTOR inhibitor Originator HEC Pharm Developer HEC Pharm; Sunshine Lake Pharma Class Anti-inflammatories; Antifibrotics; Isoenzymes Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors …